Pharmaceutical innovation and the burden of disease in developing and developed countries

Journal of Medicine and Philosophy

Volumn 30, Issue 6, 2005, Pages 663-690

  Lichtenberg, Frank R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Pharmaceutical innovation; Research and Development (R D)

Indexed keywords

ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIDIARRHEAL AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIMIGRAINE AGENT; ANTISCHISTOSOMAL AGENT; ANTIULCER AGENT; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CYTOSTATIC AGENT; DIPHTHERIA ANTIBODY; DONEPEZIL; GALANTAMINE; HEPATITIS ANTIBODY; IMMUNOGLOBULIN; LEPROSTATIC AGENT; MEASLES ANTIBODY; RIVASTIGMINE; TACRINE; TETANUS ANTIBODY; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; DATA BASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS; DIARRHEA; DIPHTHERIA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; EPILEPSY; GLAUCOMA; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LEPROSY; MAJOR DEPRESSION; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MEASLES; MEASUREMENT; MIGRAINE; MORBIDITY; PARKINSON DISEASE; PEPTIC ULCER; PERTUSSIS; REVIEW; SCHISTOSOMIASIS; TETANUS; TREATMENT INDICATION; TUBERCULOSIS; UNITED STATES; WORLD HEALTH ORGANIZATION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG INDUSTRY; HUMANS; MORBIDITY; MORTALITY; WORLD HEALTH ORGANIZATION;

EID: 30544439246     PISSN: 03605310     EISSN: None     Source Type: Journal    
DOI: 10.1080/03605310500421421     Document Type: Review

References (38)

1. Baltagi, B., Bratberg, E. & Holmas, T.H. (2003). A panel data study of physicians' labor supply: The case of Norway. CESifo Working Paper Series CESifo Working Paper No., CESifo GmbH. [On-line]. Available: http://ideas.repec.org/p/ces/ceswps/_895.html. Accessed: November 8, 2005.
2. Barro, J.R. Beaulieu N.D. (2000). Selection and improvement: Physician responses to financial incentives. NBER Working Paper No. 10017. Cambridge: National Bureau of Economic Research.
3. Bushmann, C., & Passmore, G. (1988). Physician participation in the Missouri Medicaid program. Missouri Medicine, 85(10), 659-665.
4. Coburn, A.F., Long, S.H., & Marquis, M.S. (1999). Effects of changing Medicaid fees on physician participation and enrollee access. Inquiry, 36(3), 265-279.
5. Currie, J., Gruber, J., & Fischer, M. (1995). Physician payments and infant mortality: Evidence from Medicaid fee policy. American Economic Review, 85(2), 106-111.
6. Davidson, S.M., Perloff, J.D., Kletke, P.R., Schiff, D.W., & Connelly, J.P. (1983). Full and limited Medicaid participation among pediatricians. Pediatrics, 72(4), 552-559.
7. DiMasi, J. (1994). Risks, regulation, and rewards in new drug development in the U.S. Regulatory Toxicology and Pharmacology, 19(2), 228-235.
8. Ellis, R.P., & Gurol, I. (2002). Health plan entry and exit in the Medicare managed care market. Boston University, Boston, MA. [On-line]. Available: http://econ.bu.edu/Ellis/Papers/EllisGurolExit1106.pdf. Accessed: November 8, 2005.
9. Ellison, S.F., & Mullin, W.P. (1997). Gradual incorporation of information into stock prices: Empirical strategies. NBER Working Paper No. 6218. Cambridge: National Bureau of Economic Research. [On-line]. Available: http://www.nber.org/papers/w6218. Accessed: November 8, 2005.
10. Gaynor, M., Rebitzer, J., & Taylor, L. (2001). Incentives in HMOs. NBER Working Paper No. w8522. Cambridge: National Bureau of Economic Research. [On-line]. Available: http://www.nber.org/papers/w8522. Accessed: November 8, 2005.
11. Grabowski, H., & Vernon, J. (1994). Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics, 13(4), 383-406.
12. Hadley, J. (1979). Physician participation in Medicaid: Evidence from California. Health Services Research, 14(4), 266-280.
13. Hall, R.E., & Jones, C.I. (1999). Why do some countries produce so much more output per worker than others?. Quarterly Journal of Economics, 114(1), 83-116.
14. Jones, C. (1998). Introduction to economic growth. New York: Norton.
15. Kremer M. (2000a). Creating markets for new vaccines, part I: Rationale. NBER Working Paper No. 7716. Cambridge: National Bureau of Economic Research.
16. Kremer M. (2000b). Creating markets for new vaccines, part II: Design issues. NBER Working Paper No. 7717. Cambridge: National Bureau of Economic Research.
17. Levin, C.T., Klevorick, A.K., Nelson, R.R., & Winter, S.G. (1987). Appropriating the returns from industrial R&D. Brookings Papers on Economic Activity, 3, 783-820.
18. Lichtenberg, F. (1986). Energy prices and induced innovation. Research Policy, 15, 67-75.
19. Lichtenberg, F. (1987). Changing market opportunities and the structure of R&D investment: The case of energy. Energy Economics, 9(3), 154-158.
20. Lichtenberg, F. (1988). The private R&D investment response to federal design and technical competitions. American Economic Review, 78(3), 550-559.
21. Lichtenberg, F. (2001). The allocation of publicly-funded biomedical research. In E. Berndt & D. Cutler (eds.), Medical care output and productivity (pp. 565-89). Chicago: University of Chicago Press.
22. Lichtenberg, F. (2003). Pharmaceutical innovation, mortality reduction, and economic growth. In K.M. Murphy & R.H. Topel (eds.), Measuring the gains from medical research: An economic approach (pp. 74-109). Chicago: University of Chicago Press.
23. Lichtenberg, F. (2004a). Sources of US longevity increase, 1960-2001. Quarterly Review of Economics and Finance, 44(3), 369-389.
24. Lichtenberg, F. (2004b). Public policy and innovation in the U.S. pharmaceutical industry. In D. Holtz-Eakin & H.S. Rosen (eds.), Public policy and the economics of entrepreneurship (pp. 83-113). Cambridge: MIT Press.
25. Lichtenberg, F. (2004c). The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program. NBER Working Paper No. w10884. Cambridge: National Bureau of Economic Research. [On-line]. Available: http://www.nber.org/papers/w10884. Accessed: November 8, 2005.
26. Lichtenberg, F. (2005a). Availability of new drugs and Americans' ability to work. Journal of Occupational and Environmental Medicine, 47(4), 373-380.
27. Lichtenberg, F. (2005b). The impact of new drug launches on longevity: Evidence from longitudinal disease-level data from 52 countries, 1982-2001. International Journal of Health Care Finance and Economics, 5(1), 47-73.
28. Mansfield, E. (1986). Patents and innovation: An empirical study. Management Science, 32(2), 173-181.
29. Mitchell, J.B. (1983). Medicaid participation by medical and surgical specialists. Medical Care, 21(9), 929-938.
30. Mosby (2004). Mosby's drug consult 2004. St. Louis: Mosby, Inc.
31. Nichols N.A. 1994 Scientific management at Merck: An interview with CFO Judy Lewent. Harvard Business Review, January.
32. Office of Technology Assessment 1993 Pharmaceutical R&D: Costs, risks, and rewards. Washington: U.S. GPO.
33. Patricia Y., Wang R., & Wang L. (2003). The impact of price regulation on the launch delay of new drugs - A study of twenty-five major markets in the 1990s. NBER Working Paper No. 9874. Cambridge: National Bureau of Economic Research.
34. Popp, D. (2001). Induced innovation and energy prices. The American Economic Review, 92(1), 160-180.
35. Schmookler, J. (1966). Invention and economic growth. Cambridge: Harvard University Press.
36. Smith, J.C., Hartwig, L., Laufer, R.H., Cole, W.Q., Larsen, L.G., Jackson, A.J., & Hill, E. (1991). Physician participation in the Mississippi Medicaid program: 1989-90. Journal of Mississippi State Medical Association, 32(1), 1-8.
37. Stern S., Porter M.E., & Furman J.L. (2000). The Determinants of national innovative capacity. NBER Working Paper No. 7876. Cambridge: National Bureau of Economic Research.
38. Weaver, M., Weaver, R.B., Abney, R.L., & Watson, D.G. (1986). Mississippi physician participation in Medicaid. Journal of the Mississippi State Medical Association, 27(6), 159-162.